Global Cardiometabolic Drug Market Research Report 2022

Report Format: PDF   |   Report ID: 5378585   |   Published Date: July 2022   |   Pages:  83  

Choose License
Cardiometabolic Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cardiometabolic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
    Impaired Glucose Tolerance Drug
    Insulin Resistance Drug
    Hypertension Drug
    Dyslipidemia Drug
    Central Adiposity Drug
Segment by Application
    Hospital Pharmacies
    Online Pharnacies
    Retail Pharmacies
By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA
By Company
    Gilead Sciences
    AbbVie
    Sanofi
    InovoBiologic
    Carmel Biosciences
    Genfit
    Kochi Prefecture
    Besins Healthcare
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Cardiometabolic Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Impaired Glucose Tolerance Drug
        1.2.3 Insulin Resistance Drug
        1.2.4 Hypertension Drug
        1.2.5 Dyslipidemia Drug
        1.2.6 Central Adiposity Drug
    1.3 Market by Application
        1.3.1 Global Cardiometabolic Drug Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospital Pharmacies
        1.3.3 Online Pharnacies
        1.3.4 Retail Pharmacies
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Cardiometabolic Drug Market Perspective (2017-2028)
    2.2 Cardiometabolic Drug Growth Trends by Region
        2.2.1 Cardiometabolic Drug Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Cardiometabolic Drug Historic Market Size by Region (2017-2022)
        2.2.3 Cardiometabolic Drug Forecasted Market Size by Region (2023-2028)
    2.3 Cardiometabolic Drug Market Dynamics
        2.3.1 Cardiometabolic Drug Industry Trends
        2.3.2 Cardiometabolic Drug Market Drivers
        2.3.3 Cardiometabolic Drug Market Challenges
        2.3.4 Cardiometabolic Drug Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Cardiometabolic Drug Players by Revenue
        3.1.1 Global Top Cardiometabolic Drug Players by Revenue (2017-2022)
        3.1.2 Global Cardiometabolic Drug Revenue Market Share by Players (2017-2022)
    3.2 Global Cardiometabolic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Cardiometabolic Drug Revenue
    3.4 Global Cardiometabolic Drug Market Concentration Ratio
        3.4.1 Global Cardiometabolic Drug Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Cardiometabolic Drug Revenue in 2021
    3.5 Cardiometabolic Drug Key Players Head office and Area Served
    3.6 Key Players Cardiometabolic Drug Product Solution and Service
    3.7 Date of Enter into Cardiometabolic Drug Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiometabolic Drug Breakdown Data by Type
    4.1 Global Cardiometabolic Drug Historic Market Size by Type (2017-2022)
    4.2 Global Cardiometabolic Drug Forecasted Market Size by Type (2023-2028)
5 Cardiometabolic Drug Breakdown Data by Application
    5.1 Global Cardiometabolic Drug Historic Market Size by Application (2017-2022)
    5.2 Global Cardiometabolic Drug Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Cardiometabolic Drug Market Size (2017-2028)
    6.2 North America Cardiometabolic Drug Market Size by Country (2017-2022)
    6.3 North America Cardiometabolic Drug Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Cardiometabolic Drug Market Size (2017-2028)
    7.2 Europe Cardiometabolic Drug Market Size by Country (2017-2022)
    7.3 Europe Cardiometabolic Drug Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Cardiometabolic Drug Market Size (2017-2028)
    8.2 Asia-Pacific Cardiometabolic Drug Market Size by Country (2017-2022)
    8.3 Asia-Pacific Cardiometabolic Drug Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Cardiometabolic Drug Market Size (2017-2028)
    9.2 Latin America Cardiometabolic Drug Market Size by Country (2017-2022)
    9.3 Latin America Cardiometabolic Drug Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Cardiometabolic Drug Market Size (2017-2028)
    10.2 Middle East & Africa Cardiometabolic Drug Market Size by Country (2017-2022)
    10.3 Middle East & Africa Cardiometabolic Drug Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Gilead Sciences
        11.1.1 Gilead Sciences Company Detail
        11.1.2 Gilead Sciences Business Overview
        11.1.3 Gilead Sciences Cardiometabolic Drug Introduction
        11.1.4 Gilead Sciences Revenue in Cardiometabolic Drug Business (2017-2022)
        11.1.5 Gilead Sciences Recent Development
    11.2 AbbVie
        11.2.1 AbbVie Company Detail
        11.2.2 AbbVie Business Overview
        11.2.3 AbbVie Cardiometabolic Drug Introduction
        11.2.4 AbbVie Revenue in Cardiometabolic Drug Business (2017-2022)
        11.2.5 AbbVie Recent Development
    11.3 Sanofi
        11.3.1 Sanofi Company Detail
        11.3.2 Sanofi Business Overview
        11.3.3 Sanofi Cardiometabolic Drug Introduction
        11.3.4 Sanofi Revenue in Cardiometabolic Drug Business (2017-2022)
        11.3.5 Sanofi Recent Development
    11.4 InovoBiologic
        11.4.1 InovoBiologic Company Detail
        11.4.2 InovoBiologic Business Overview
        11.4.3 InovoBiologic Cardiometabolic Drug Introduction
        11.4.4 InovoBiologic Revenue in Cardiometabolic Drug Business (2017-2022)
        11.4.5 InovoBiologic Recent Development
    11.5 Carmel Biosciences
        11.5.1 Carmel Biosciences Company Detail
        11.5.2 Carmel Biosciences Business Overview
        11.5.3 Carmel Biosciences Cardiometabolic Drug Introduction
        11.5.4 Carmel Biosciences Revenue in Cardiometabolic Drug Business (2017-2022)
        11.5.5 Carmel Biosciences Recent Development
    11.6 Genfit
        11.6.1 Genfit Company Detail
        11.6.2 Genfit Business Overview
        11.6.3 Genfit Cardiometabolic Drug Introduction
        11.6.4 Genfit Revenue in Cardiometabolic Drug Business (2017-2022)
        11.6.5 Genfit Recent Development
    11.7 Kochi Prefecture
        11.7.1 Kochi Prefecture Company Detail
        11.7.2 Kochi Prefecture Business Overview
        11.7.3 Kochi Prefecture Cardiometabolic Drug Introduction
        11.7.4 Kochi Prefecture Revenue in Cardiometabolic Drug Business (2017-2022)
        11.7.5 Kochi Prefecture Recent Development
    11.8 Besins Healthcare
        11.8.1 Besins Healthcare Company Detail
        11.8.2 Besins Healthcare Business Overview
        11.8.3 Besins Healthcare Cardiometabolic Drug Introduction
        11.8.4 Besins Healthcare Revenue in Cardiometabolic Drug Business (2017-2022)
        11.8.5 Besins Healthcare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables Table 1. Global Cardiometabolic Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Impaired Glucose Tolerance Drug Table 3. Key Players of Insulin Resistance Drug Table 4. Key Players of Hypertension Drug Table 5. Key Players of Dyslipidemia Drug Table 6. Key Players of Central Adiposity Drug Table 7. Global Cardiometabolic Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Cardiometabolic Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 9. Global Cardiometabolic Drug Market Size by Region (2017-2022) & (US$ Million) Table 10. Global Cardiometabolic Drug Market Share by Region (2017-2022) Table 11. Global Cardiometabolic Drug Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 12. Global Cardiometabolic Drug Market Share by Region (2023-2028) Table 13. Cardiometabolic Drug Market Trends Table 14. Cardiometabolic Drug Market Drivers Table 15. Cardiometabolic Drug Market Challenges Table 16. Cardiometabolic Drug Market Restraints Table 17. Global Cardiometabolic Drug Revenue by Players (2017-2022) & (US$ Million) Table 18. Global Cardiometabolic Drug Market Share by Players (2017-2022) Table 19. Global Top Cardiometabolic Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Drug as of 2021) Table 20. Ranking of Global Top Cardiometabolic Drug Companies by Revenue (US$ Million) in 2021 Table 21. Global 5 Largest Players Market Share by Cardiometabolic Drug Revenue (CR5 and HHI) & (2017-2022) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Cardiometabolic Drug Product Solution and Service Table 24. Date of Enter into Cardiometabolic Drug Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Cardiometabolic Drug Market Size by Type (2017-2022) & (US$ Million) Table 27. Global Cardiometabolic Drug Revenue Market Share by Type (2017-2022) Table 28. Global Cardiometabolic Drug Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 29. Global Cardiometabolic Drug Revenue Market Share by Type (2023-2028) Table 30. Global Cardiometabolic Drug Market Size by Application (2017-2022) & (US$ Million) Table 31. Global Cardiometabolic Drug Revenue Market Share by Application (2017-2022) Table 32. Global Cardiometabolic Drug Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 33. Global Cardiometabolic Drug Revenue Market Share by Application (2023-2028) Table 34. North America Cardiometabolic Drug Market Size by Country (2017-2022) & (US$ Million) Table 35. North America Cardiometabolic Drug Market Size by Country (2023-2028) & (US$ Million) Table 36. Europe Cardiometabolic Drug Market Size by Country (2017-2022) & (US$ Million) Table 37. Europe Cardiometabolic Drug Market Size by Country (2023-2028) & (US$ Million) Table 38. Asia-Pacific Cardiometabolic Drug Market Size by Region (2017-2022) & (US$ Million) Table 39. Asia-Pacific Cardiometabolic Drug Market Size by Region (2023-2028) & (US$ Million) Table 40. Latin America Cardiometabolic Drug Market Size by Country (2017-2022) & (US$ Million) Table 41. Latin America Cardiometabolic Drug Market Size by Country (2023-2028) & (US$ Million) Table 42. Middle East & Africa Cardiometabolic Drug Market Size by Country (2017-2022) & (US$ Million) Table 43. Middle East & Africa Cardiometabolic Drug Market Size by Country (2023-2028) & (US$ Million) Table 44. Gilead Sciences Company Detail Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences Cardiometabolic Drug Product Table 47. Gilead Sciences Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 48. Gilead Sciences Recent Development Table 49. AbbVie Company Detail Table 50. AbbVie Business Overview Table 51. AbbVie Cardiometabolic Drug Product Table 52. AbbVie Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 53. AbbVie Recent Development Table 54. Sanofi Company Detail Table 55. Sanofi Business Overview Table 56. Sanofi Cardiometabolic Drug Product Table 57. Sanofi Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 58. Sanofi Recent Development Table 59. InovoBiologic Company Detail Table 60. InovoBiologic Business Overview Table 61. InovoBiologic Cardiometabolic Drug Product Table 62. InovoBiologic Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 63. InovoBiologic Recent Development Table 64. Carmel Biosciences Company Detail Table 65. Carmel Biosciences Business Overview Table 66. Carmel Biosciences Cardiometabolic Drug Product Table 67. Carmel Biosciences Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 68. Carmel Biosciences Recent Development Table 69. Genfit Company Detail Table 70. Genfit Business Overview Table 71. Genfit Cardiometabolic Drug Product Table 72. Genfit Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 73. Genfit Recent Development Table 74. Kochi Prefecture Company Detail Table 75. Kochi Prefecture Business Overview Table 76. Kochi Prefecture Cardiometabolic Drug Product Table 77. Kochi Prefecture Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 78. Kochi Prefecture Recent Development Table 79. Besins Healthcare Company Detail Table 80. Besins Healthcare Business Overview Table 81. Besins Healthcare Cardiometabolic Drug Product Table 82. Besins Healthcare Revenue in Cardiometabolic Drug Business (2017-2022) & (US$ Million) Table 83. Besins Healthcare Recent Development Table 84. Research Programs/Design for This Report Table 85. Key Data Information from Secondary Sources Table 86. Key Data Information from Primary Sources List of Figures Figure 1. Global Cardiometabolic Drug Market Share by Type: 2021 VS 2028 Figure 2. Impaired Glucose Tolerance Drug Features Figure 3. Insulin Resistance Drug Features Figure 4. Hypertension Drug Features Figure 5. Dyslipidemia Drug Features Figure 6. Central Adiposity Drug Features Figure 7. Global Cardiometabolic Drug Market Share by Application in 2021 & 2028 Figure 8. Hospital Pharmacies Case Studies Figure 9. Online Pharnacies Case Studies Figure 10. Retail Pharmacies Case Studies Figure 11. Cardiometabolic Drug Report Years Considered Figure 12. Global Cardiometabolic Drug Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Cardiometabolic Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Cardiometabolic Drug Market Share by Region: 2021 VS 2028 Figure 15. Global Cardiometabolic Drug Market Share by Players in 2021 Figure 16. Global Top Cardiometabolic Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiometabolic Drug as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Cardiometabolic Drug Revenue in 2021 Figure 18. North America Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. North America Cardiometabolic Drug Market Share by Country (2017-2028) Figure 20. United States Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Cardiometabolic Drug Market Share by Country (2017-2028) Figure 24. Germany Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. France Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. U.K. Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Italy Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Russia Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Nordic Countries Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Cardiometabolic Drug Market Share by Region (2017-2028) Figure 32. China Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Japan Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. South Korea Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Southeast Asia Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. India Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Australia Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Cardiometabolic Drug Market Share by Country (2017-2028) Figure 40. Mexico Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Brazil Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Cardiometabolic Drug Market Share by Country (2017-2028) Figure 44. Turkey Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Saudi Arabia Cardiometabolic Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Gilead Sciences Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 47. AbbVie Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 48. Sanofi Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 49. InovoBiologic Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 50. Carmel Biosciences Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 51. Genfit Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 52. Kochi Prefecture Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 53. Besins Healthcare Revenue Growth Rate in Cardiometabolic Drug Business (2017-2022) Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research